Common Nasal Spray May Cut COVID-19 Risk, Study Finds
A study by the University of the Saarland has discovered that a common antihistamine nasal spray, Azelastin, can significantly reduce the risk of infection with Sars-CoV-2, including the coronavirus. The nasal spray is currently prescribed to patients with pollen allergies and is available over the counter.
The clinical study, involving 450 participants, found that only 2.2% of those using Azelastin were infected with Sars-CoV-2, compared to 6.7% in the placebo group. The illness was also less severe in the Azelastin group, with fewer respiratory infections. The nasal spray was found to protect against rhinoviruses, the classic cold viruses, with only 1.8% of users developing an infection, compared to 6.3% in the control group. The lead researcher suggests that the nasal spray could be a supplement to existing protective measures for risk groups during high-incidence phases or before upcoming trips.
As temperatures fall in Berlin, the risk of catching a virus, including the coronavirus, increases. The Robert Koch Institute is reporting an increasing number of coronavirus cases in the city. Current investigations show that Azelastin nasal spray, used 'on-demand', can significantly reduce the risk of SARS-CoV-2 infection and also decrease infections with other respiratory viruses. However, experts emphasize the need for larger, multicenter clinical trials to confirm these results and evaluate the potential against other pathogens beyond COVID-19.
The nasal spray Azelastin, already available over the counter, has shown promising results in reducing the risk of SARS-CoV-2 infection and other respiratory viruses. As the weather turns colder and virus cases rise, this could provide an additional layer of protection. However, further research is needed to confirm these findings and explore its potential against other pathogens.
Read also:
- Stephanie Estremera Gonzalez: From Medical Assistant to Residential Manager at The Point/Arc
- Impact of a Government Shutdown on Citizens
- Medical Specialist Based in Visakhapatnam
- Individuals in New York afflicted by Legionnaires' disease have legitimate legal entitlements. Here's some essential information on the matter.
